Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.

Al-Kali A, Ozer H.

Oncology (Williston Park). 2006 Dec;20(14 Suppl 9):7-12. Review.

3.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.

Gerlier L, Lamotte M, Awada A, Bosly A, Bries G, Cocquyt V, Focan C, Henry S, Lalami Y, Machiels JP, Mebis J, Straetmans N, Verhoeven D, Somers L.

BMC Cancer. 2010 Nov 23;10:642. doi: 10.1186/1471-2407-10-642.

4.

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.

Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD007913. doi: 10.1002/14651858.CD007913.pub2. Review.

PMID:
23076939
5.
6.

Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy.

Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL.

J Am Geriatr Soc. 2010 Oct;58(10):1885-95. doi: 10.1111/j.1532-5415.2010.03081.x. Epub 2010 Sep 14.

PMID:
20840455
7.

Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.

Lyman GH, Kleiner JM.

J Natl Compr Canc Netw. 2007 Feb;5(2):217-28.

PMID:
17335690
8.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer..

Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20.

PMID:
21095116
9.

Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.

Daniel DB, Crawford J; National Comprehensive Cancer Network..

Curr Hematol Rep. 2005 Nov;4(6):441-5. Review.

PMID:
16232380
10.

Identification of cancer patients at high risk of febrile neutropenia.

Scott S.

Am J Health Syst Pharm. 2002 Aug 1;59(15 Suppl 4):S16-9. Review.

PMID:
12166033
11.

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.

Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J.

Curr Med Res Opin. 2011 Jan;27(1):79-86. doi: 10.1185/03007995.2010.536527. Epub 2010 Nov 22.

PMID:
21091127
12.

Balancing the benefits and costs of colony-stimulating factors: a current perspective.

Lyman GH.

Semin Oncol. 2003 Aug;30(4 Suppl 13):10-7. Review.

PMID:
14508715
13.

Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.

McCune JS, Sullivan SD, Blough DK, Clarke L, McDermott C, Malin J, Ramsey S.

Pharmacotherapy. 2012 Jan;32(1):7-19. doi: 10.1002/PHAR.1008.

PMID:
22392824
14.

The colony-stimulating factors: use to prevent and treat neutropenia and its complications.

Komrokji RS, Lyman GH.

Expert Opin Biol Ther. 2004 Dec;4(12):1897-910. Review.

PMID:
15571452
15.

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.

Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M, Schwenkglenks M; Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU)..

Br J Haematol. 2009 Mar;144(5):677-85. doi: 10.1111/j.1365-2141.2008.07514.x. Epub 2008 Dec 1.

16.

Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.

Lyman GH, Kleiner JM.

Cancer Treat Res. 2011;157:145-65. doi: 10.1007/978-1-4419-7073-2_9. Review.

PMID:
21052955
17.

[Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].

Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.

Zhonghua Yi Xue Za Zhi. 2006 Dec 26;86(48):3414-9. Chinese.

PMID:
17313855
18.

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party..

Eur J Cancer. 2006 Oct;42(15):2433-53. Epub 2006 Jun 5. Review.

PMID:
16750358
19.

Risk assessment in oncology clinical practice. From risk factors to risk models.

Lyman GH.

Oncology (Williston Park). 2003 Nov;17(11 Suppl 11):8-13. Review.

Supplemental Content

Support Center